Description: enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Home Page: www.engene.com
7171 Rue Frederick Banting
Saint-Laurent,
QC
H4S 1Z9
Canada
Phone:
514 332 4888
Officers
| Name | Title |
|---|---|
| Mr. Ronald H. W. Cooper | Chief Executive Officer & Director |
| Dr. Anthony T. Cheung Ph.D. | Co-Founder & Chief Scientific Officer |
| Mr. John C. Brown D.Sc., FRSC, Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Mr. David Ryan Daws | CFO & Head of Business Development |
| Ms. Joan Connolly | Chief Technology Officer |
| Mr. Lee G. Giguere | Chief Legal Officer & Corporate Secretary |
| Ms. Sharon Tan | VP of Project Management & Head of Program Management |
| Mr. Paul Erickson | Non-Executive Director |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4585 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2023-11-01 |
| Fiscal Year End: | October |
| Full Time Employees: | 31 |